IPCALAB

IPCA LABORATORIES

Large Cap BSE: 524494 NSE: IPCALAB
₹856.7
-7.1 (-0.82%)
  • Advice
  • Hold
As on 07 December, 2022 | 04:30

Ipca Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in IPCA LABORATORIES

Start SIP

Ipca Laboratories Share Price

Ipca Laboratories Share Returns

  • Over 1 Month -5.33%
  • Over 3 Month -2.97%
  • Over 6 Month -0.82%
  • Over 1 Year -15%

Ipca Laboratories Key Statistics

P/E Ratio 35.4
PEG Ratio -0.9
Market Cap Cr 21,735
Price to Book Ratio 3.9
EPS 34
Dividend 0.5
Relative Strength Index 39.15
Money Flow Index 42.98
MACD Signal -8.89
Average True Range 19.07

Ipca Laboratories Investment Rating

  • Master Rating:
  • Ipca Laboratories has an operating revenue of Rs. 5,906.26 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 19% is great, ROE of 16% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 110 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 1,4851,4691,1681,3281,4241,4791,041
Operating Expenses Qtr Cr 1,2131,2129891,0171,0651,085824
Operating Profit Qtr Cr 272257179312359394217
Depreciation Qtr Cr 55535251515049
Interest Qtr Cr 9731112
Tax Qtr Cr 77722754647234
Net Profit Qtr Cr 168144110218258285151

Ipca Laboratories Technicals

EMA & SMA

Current Price
856.7
-7.1 (-0.82%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 872.31
  • 50 Day
  • 886.88
  • 100 Day
  • 905.82
  • 200 Day
  • 938.57
  • 20 Day
  • 868.89
  • 50 Day
  • 891.9
  • 100 Day
  • 915.32
  • 200 Day
  • 940.25

Ipca Laboratories Resistance and Support

PIVOT
₹865.82
Resistance
First Resistance 869.59
Second Resistance 875.37
Third Resistance 879.14
RSI 39.15
MFI 42.98
MACD Single Line -8.89
MACD -8.55
Support
First Resistance 860.04
Second Resistance 856.27
Third Resistance 850.49

Ipca Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 225,399 12,584,026 55.83
Week 275,971 18,639,068 67.54
1 Month 308,960 15,914,547 51.51
6 Month 319,228 16,507,280 51.71

Ipca Laboratories Result Highlights

Ipca Laboratories Synopsis

NSE-Medical-Generic Drugs

Ipca Laboratorie is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 5399.36 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2022. Ipca Laboratories Ltd. is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837.
Market Cap 21,754
Sales 5,451
Shares in Float 13.70
No of funds 250
Yield 0.47
Book Value 3.94
U/D Vol ratio 0.9
LTDebt / Equity 7
Alpha -0.07
Beta 0.47

Ipca Laboratories

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 46.29%46.29%46.29%
Mutual Funds 29.71%29.41%28.2%
Insurance Companies 3.57%3.9%4.2%
Foreign Portfolio Investors 10.57%10.61%11.02%
Financial Institutions/ Banks
Individual Investors 7.44%7.5%7.79%
Others 2.42%2.29%2.5%

Ipca Laboratories Management

Name Designation
Mr. Premchand Godha Chairman & M.D & CEO
Mr. Ajit Kumar Jain Joint Managing Director & CFO
Mr. Pranay Godha Executive Director
Mr. Prashant Godha Executive Director
Mr. Anand T Kusre Independent Director
Mr. Dev Parkash Yadava Independent Director
Dr.(Mrs.) Manisha Premnath Independent Director
Mr. Kamal Kishore Seth Independent Director

Ipca Laboratories Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Ipca Laboratories Corporate Action

Date Purpose Remarks
2022-11-11 Quarterly Results & Interim Dividend
2022-08-10 Quarterly Results
2022-05-24 Audited Results & Amalgamation
2022-02-14 Quarterly Results
2021-11-13 Qtr Results, Int. Dividend & Stock Split
Date Purpose Remarks
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 49709
ICICI Prudential Balanced Advantage Fund Growth 44002
HDFC Mid-Cap Opportunities Fund Growth 35120
ICICI Prudential Bluechip Fund Growth 34823
Parag Parikh Flexi Cap Regular Growth 27712

Ipca Laboratories FAQs

What is Share Price of Ipca Laboratories ?

Ipca Laboratories share price is ₹856 As on 07 December, 2022 | 04:16

What is the Market Cap of Ipca Laboratories ?

The Market Cap of Ipca Laboratories is ₹21734.8 Cr As on 07 December, 2022 | 04:16

What is the P/E ratio of Ipca Laboratories ?

The P/E ratio of Ipca Laboratories is 35.4 As on 07 December, 2022 | 04:16

What is the PB ratio of Ipca Laboratories ?

The PB ratio of Ipca Laboratories is 3.9 As on 07 December, 2022 | 04:16

Q2FY23